Patents by Inventor Xianhui Wang
Xianhui Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12287445Abstract: A coal rock interface directional detection device based on elastic waves includes: a probe body including an elastic wave receiving device and an elastic wave excitation device spaced set at the top; a protective tube with one end connected to the adapter. The protective tube includes a collection circuit board inside the protective tube, and the collection circuit board is electrically connected to the elastic wave receiving device and the elastic wave excitation device; a sleeve, installed outside the protective tube, with one end connected to the side of the probe body near the adapter and with the other end connected to the side of the protective tube away from the adapter; and a control host, wirelessly connected with the acquisition circuit board. A coal rock interface directional detection method based on elastic waves applied in the coal rock interface directional detection device is also disclosed.Type: GrantFiled: November 7, 2024Date of Patent: April 29, 2025Assignee: CHINA UNIVERSITY OF MINING AND TECHNOLOGY, BEIJINGInventors: Yifan Zeng, Xianhui Wang, Qiang Wu, Chunsheng Liu, Fei Chen, Jia Zhao, Zhuangjie Cui
-
Publication number: 20250112716Abstract: Provided are a configuration method and apparatus for dual-mode converged communication, and a dual-mode converged communication system. The method includes: determining a first operating frequency band of power line communication (PLC) and a second operating frequency band of radio frequency (RF) communication; and configuring a second frequency band number of the second operating frequency band based on a first frequency band number of the first operating frequency band, such that a high-order harmonic frequency of a first operating clock of the PLC and a high-order harmonic frequency of a second operating clock of the RF communication do not overlap with the first operating frequency band or the second operating frequency band. This can reduce an impact of multiplicative noise generated by harmonic superposition and an impact of noise generated by a CPU during operation on performance of a dual-mode converged communication unit, improving transmission efficiency of dual-mode converged communication.Type: ApplicationFiled: August 14, 2023Publication date: April 3, 2025Inventors: Zheng Li, Qixin Gao, Kunpeng Xu, Hongguang Dai, Qian Zhang, Xianhui Wang, Weiqi Hao, Zhanxia Wu
-
Publication number: 20230370362Abstract: Provided are a networking method, communication method, and communication system for a multi-mode communication device, a device, and a chip. The networking method includes: sending response information about available communication modes between a network access node and a to-be-connected node to the network access node, where the available communication modes are divided into a plurality of sets, and modes in each of the sets are incompatible with each other, and modes in different sets are compatible with each other; and locking an optimal mode, selected from each of the sets based on the response information, as handshake information between the two nodes when a preset negotiation result is met, such that the network access node reports corresponding routing information, and a root node updates networking routing information.Type: ApplicationFiled: June 5, 2023Publication date: November 16, 2023Inventors: Yubo Wang, Xianhui Wang, Zheng Li, Kunpeng Xu, Hongguang Dai, Deyong Xiao, Weiqi Hao, Dan Luo, Jin Shao, Yujie Xu, Zhanxia Wu, Wei Liu
-
Publication number: 20230327837Abstract: Disclosed are a beacon timeslot allocation method, apparatus, and device. The method includes: determining, based on a type of a beacon frame sent by a node in a system on a highspeed radio frequency (HRF) link, a node sending a standard beacon frame as a first-type node, and a node sending a simplified beacon frame as a second-type node; and in a process of sending a beacon frame on the HRF link by one first-type node, scheduling at least one first-type node and/or second-type node that have/has not been scheduled to perform sending on a highspeed power line carrier (HPLC) link yet to send a beacon frame on the HPLC link, where the scheduled first-type node and/or second-type node do/does not include the one first-type node or a node on a path between the one first-type node and a central coordinator (CCO) in the system.Type: ApplicationFiled: May 10, 2023Publication date: October 12, 2023Inventors: Dongyan Zhao, Dan Luo, Zheng Li, Deyong Xiao, Xianhui Wang, Kunpeng Xu, Xiaohui Zhang, Fuyu Pei, Jin Shao, Qian Zhang
-
Publication number: 20220364197Abstract: A preparation method of glassless grain-oriented silicon steel includes the following operations. During a decarburization annealing, a thickness of an oxide film on a surface of strip is 1.5-2.5 ?m; an atomic weight ratio of Si element and Fe element in the oxide film satisfies: Si/(Si+Fe)?0.76; during a high-temperature annealing, a cooling stage includes sequentially: cooling with an inner cover when a temperature drops from 1200° C. to 500° C.; wherein a protective gas is a mixed gas containing nitrogen and hydrogen, and a volume percentage of the hydrogen in the mixed gas is >3%; cooling with the inner cover when the temperature drops from 500° C. to 200° C.; wherein the protective gas is nitrogen; and cooling in air by removing the inner cover when the temperature is <200° C.Type: ApplicationFiled: August 1, 2022Publication date: November 17, 2022Applicants: SHOUGANG ZHIXIN QIAN'AN ELECTROMAGNETIC MATERIAL CO., LTD., BEIJING SHOUGANG CO., LTD.Inventors: Xianhui WANG, Qian GAO, Maolin SUN, Jian GONG, Huiming XIAO, Zhaoyue LIU, Renhao TENG, Songshan ZHAO, Zhiyuan HU, Jiebin QI, Xuechang YOU, Ruifeng LI, Donghe SONG, Aixing WANG
-
Patent number: 11149092Abstract: Receptor protein kinases (RPTKs) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over 5 half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets. A large-scale loss-of-function analysis of tyrosine kinases using RNA interference in the clinically relevant Erb-B2 positive, BT474 breast cancer cell line showed that Bruton's tyrosine kinase (BTK), a cytosolic, non-receptor tyrosine kinase that has been extensively studied for its role in B cell development, is required, in altered form, for BT474 10 breast cancer survival. This alternative form contains an amino-terminal extension that is also present in tumorigenic breast cells at significantly higher levels than in normal breast cells.Type: GrantFiled: May 1, 2017Date of Patent: October 19, 2021Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORKInventors: Douglas S. Conklin, Cheryl Eifert, Antonis Kourtidis, Xianhui Wang, Leila Kokabee
-
Publication number: 20200289513Abstract: Embodiments of the disclosure find application in the field of cancer therapy. Receptor protein kinases (RPTKs) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets.Type: ApplicationFiled: May 31, 2020Publication date: September 17, 2020Inventors: Xianhui Wang, Douglas S. Conklin
-
Patent number: 10705986Abstract: Embodiments of this application provide a flash interface controller and an operation command processing method, and relate to the field of data storage. Programmable first type microcode and second type microcode are introduced to a flash interface controller. The first type microcode can be modified through programming to adapt to a procedure of parsing an operation command of a new protocol, and the second type microcode can be modified through programming to adapt to a flash bus operation required by a new flash interface standard. An operation command can be parsed by only fixing logics of physical modules in the flash interface controller and reading first type microcode and second type microcode that are related to the operation command. Therefore, various protocols and flash interface standards can be adapted to, and flexibility is good.Type: GrantFiled: June 20, 2019Date of Patent: July 7, 2020Assignee: Huawei Technologies Co. Ltd.Inventors: Xianhui Wang, Rui Huang, You Li
-
Patent number: 10668068Abstract: Embodiments of the invention find application in the field of cancer therapy. Receptor protein kinases (RPTKs) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets.Type: GrantFiled: October 7, 2015Date of Patent: June 2, 2020Assignee: The Research Foundation For The State University Of New YorkInventors: Xianhui Wang, Douglas S. Conklin
-
Patent number: 10558593Abstract: Embodiments of this application provide a flash interface controller and an operation command processing method, and relate to the field of data storage. Programmable first type microcode and second type microcode are introduced to a flash interface controller. The first type microcode can be modified through programming to adapt to a procedure of parsing an operation command of a new protocol, and the second type microcode can be modified through programming to adapt to a flash bus operation required by a new flash interface standard. An operation command can be parsed by only fixing logics of physical modules in the flash interface controller and reading first type microcode and second type microcode that are related to the operation command. Therefore, various protocols and flash interface standards can be adapted to, and flexibility is good.Type: GrantFiled: June 20, 2019Date of Patent: February 11, 2020Assignee: Huawei Technologies Co. Ltd.Inventors: You Li, Rui Huang, Xianhui Wang
-
Publication number: 20190303314Abstract: Embodiments of this application provide a flash interface controller and an operation command processing method, and relate to the field of data storage. Programmable first type microcode and second type microcode are introduced to a flash interface controller. The first type microcode can be modified through programming to adapt to a procedure of parsing an operation command of a new protocol, and the second type microcode can be modified through programming to adapt to a flash bus operation required by a new flash interface standard. An operation command can be parsed by only fixing logics of physical modules in the flash interface controller and reading first type microcode and second type microcode that are related to the operation command. Therefore, various protocols and flash interface standards can be adapted to, and flexibility is good.Type: ApplicationFiled: June 20, 2019Publication date: October 3, 2019Inventors: You LI, Rui HUANG, Xianhui WANG
-
Patent number: 10421820Abstract: Receptor protein kinases (RPTKs) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets. A large-scale loss-of-function analysis of tyrosine kinases using RNA interference in the clinically relevant Erb-B2 positive, BT474 breast cancer cell line showed that Bruton's tyrosine kinase (BTK), a cytosolic, non-receptor tyrosine kinase that has been extensively studied for its role in B cell development, is required, in altered form, for BT474 breast cancer survival. This alternative form contains an amino-terminal extension that is also present in tumorigenic breast cells at significantly higher levels than in normal breast cells. Thus, embodiments of the invention find application in the field of cancer therapy.Type: GrantFiled: September 6, 2016Date of Patent: September 24, 2019Assignee: University Of New YorkInventors: Douglas S. Conklin, Xianhui Wang, Leila Kokabee
-
Publication number: 20170335011Abstract: Receptor protein kinases (RPTKs) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over 5 half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets. A large-scale loss-of-function analysis of tyrosine kinases using RNA interference in the clinically relevant Erb-B2 positive, BT474 breast cancer cell line showed that Bruton's tyrosine kinase (BTK), a cytosolic, non-receptor tyrosine kinase that has been extensively studied for its role in B cell development, is required, in altered form, for BT474 10 breast cancer survival. This alternative form contains an amino-terminal extension that is also present in tumorigenic breast cells at significantly higher levels than in normal breast cells.Type: ApplicationFiled: May 1, 2017Publication date: November 23, 2017Inventors: Douglas Conklin, Cheryl Eifert, Antonis Kourtidis, Xianhui Wang, Leila Kokabee
-
Publication number: 20170189404Abstract: Receptor protein kinases (RPTKs) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets. A large-scale loss-of-function analysis of tyrosine kinases using RNA interference in the clinically relevant Erb-B2 positive, BT474 breast cancer cell line showed that Bruton's tyrosine kinase (BTK), a cytosolic, non-receptor tyrosine kinase that has been extensively studied for its role in B cell development, is required, in altered form, for BT474 breast cancer survival. This alternative form contains an amino-terminal extension that is also present in tumorigenic breast cells at significantly higher levels than in normal breast cells. Thus, embodiments of the invention find application in the field of cancer therapy.Type: ApplicationFiled: September 6, 2016Publication date: July 6, 2017Inventors: Douglas S Conklin, Xianhui Wang, Leila Kokabee
-
Patent number: 9637554Abstract: Receptor protein kinases (RPTKs) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets. A large-scale loss-of-function analysis of tyrosine kinases using RNA interference in the clinically relevant Erb-B2 positive, BT474 breast cancer cell line showed that Bruton's tyrosine kinase (BTK), a cytosolic, non-receptor tyrosine kinase that has been extensively studied for its role in B cell development, is required, in altered form, for BT474 breast cancer survival. This alternative form contains an amino-terminal extension that is also present in tumorigenic breast cells at significantly higher levels than in normal breast cells.Type: GrantFiled: August 4, 2015Date of Patent: May 2, 2017Assignee: The Research Foundation For The State University Of New YorkInventors: Douglas S. Conklin, Cheryl Eifert, Antonis Kourtidis, Xianhui Wang, Leila Kokabee
-
Publication number: 20170100401Abstract: Embodiments of the invention find application in the field of cancer therapy. Receptor protein kinases (RPTKs) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets.Type: ApplicationFiled: October 7, 2015Publication date: April 13, 2017Inventors: Xianhui Wang, Douglas S. Conklin
-
Publication number: 20160206646Abstract: Receptor protein kinases (RPTKs) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets. A large-scale loss-of-function analysis of tyrosine kinases using RNA interference in the clinically relevant Erb-B2 positive, BT474 breast cancer cell line showed that Bruton's tyrosine kinase (BTK), a cytosolic, non-receptor tyrosine kinase that has been extensively studied for its role in B cell development, is required, in altered form, for BT474 breast cancer survival. This alternative form contains an amino-terminal extension that is also present in tumorigenic breast cells at significantly higher levels than in normal breast cells.Type: ApplicationFiled: August 20, 2014Publication date: July 21, 2016Inventors: Douglas S. Conklin, Cheryl Eifert, Antonis Kourtidis, Xianhui Wang, Leila Kokabee
-
Publication number: 20160053024Abstract: Receptor protein kinases (RPTKs) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets. A large-scale loss-of-function analysis of tyrosine kinases using RNA interference in the clinically relevant Erb-B2 positive, BT474 breast cancer cell line showed that Bruton's tyrosine kinase (BTK), a cytosolic, non-receptor tyrosine kinase that has been extensively studied for its role in B cell development, is required, in altered form, for BT474 breast cancer survival. This alternative form contains an amino-terminal extension that is also present in tumorigenic breast cells at significantly higher levels than in normal breast cells.Type: ApplicationFiled: August 4, 2015Publication date: February 25, 2016Inventors: Douglas S. Conklin, Cheryl Eifert, Antonis Kourtidis, Xianhui Wang, Leila Kokabee
-
Patent number: 9095592Abstract: Receptor protein kinases (RPTKs) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets. A large-scale loss-of-function analysis of tyrosine kinases using RNA interference in the clinically relevant Erb-B2 positive, BT474 breast cancer cell line showed that Bruton's tyrosine kinase (BTK), a cytosolic, non-receptor tyrosine kinase that has been extensively studied for its role in B cell development, is required, in altered form, for BT474 breast cancer survival. This alternative form contains an amino-terminal extension that is also present in tumorigenic breast cells at significantly higher levels than in normal breast cells.Type: GrantFiled: August 20, 2013Date of Patent: August 4, 2015Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORKInventors: Douglas S. Conklin, Cheryl Eifert, Antonis Kourtidis, Xianhui Wang, Leila Kokabee